GGO Vergunningendatabase

Zoekcriteria
Zoekresultaat
IM-L 20-001_000 Photanol Productie van organisch zuur met cyanobacteriƫn Ontwerpbesluit genomen
IM-MV 19-008_003 Het Nederlands Kanker Instituut Clinical Trials to Assess the Safety and/or Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells (GSK3377794), alone or in combination with other agents, in HLA-A*02:01, HLA-A*02:05 and/or HLA-A*02:06 Participants with NY-ESO-1 and/or LAGE-1a Positive Cancers 28-01-2021 Vergunning verleend
IM-MV 19-017_003 Universitair Medisch Centrum Utrecht Clinical Trials to Assess the Safety and/or Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells (GSK3377794), alone or in combination with other agents, in HLA-A*02:01, HLA-A*02:05 and/or HLA-A*02:06 Participants with NY-ESO-1 and/or LAGE-1a Positive Cancers 28-01-2021 Vergunning verleend
IM-MV 19-021_003 Erasmus MC Clinical Trials to Assess the Safety and/or Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells (GSK3377794), alone or in combination with other agents, in HLA-A*02:01, HLA-A*02:05 and/or HLA-A*02:06 Participants with NY-ESO-1 and/or LAGE-1a Positive Cancers 28-01-2021 Vergunning verleend
IM-MV 19-023_002 UMCG Clinical Trials to Assess the Safety and/or Antitumor Activity of Genetically Engineered NY-ESO-1-specific (c259) T cells (GSK3377794), alone or in combination with other agents, in HLA-A*02:01, HLA-A*02:05 and/or HLA-A*02:06 Participants with NY-ESO and/or LAGE-1a Positive Cancers 28-01-2021 Vergunning verleend
IM-MV 20-001_001 UMCG Clinical testing of TX200-TR101, an autologous antigen-specific chimeric antigen receptor (CAR) T regulatory cell therapy. 05-01-2021 Vergunning verleend
IM-MV 20-014_001 LUMC A Phase 3 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the LentiGlobin BB305 Lentiviral Vector in Subjects with Sickle Cell Disease 05-01-2021 Vergunning verleend
IM-MV 20-015_000 AMC A Clinical Study to Evaluate the Safety, Reactogenicity, Immunogenicity and Efficacy of an Ad26 and/or MVA-BN clinical vector for the prevention or treatment of infectious diseases Ontwerpbesluit genomen
IM-MV 20-017_000 LUMC Phase I/II study of lentiviral gene transfer for SCID-X1 05-01-2021 Vergunning verleend
IM-MV 20-018_000 LUMC Exposure of human test subjects to live genetically attenuated PfDmei2 (LA-GAP) malaria parasites 04-02-2021 Vergunning verleend
IM-MV 20-019_000 Stichting Katholieke Universiteit Exposure of human test subjects to live genetically attenuated PfDmei2 (LA-GAP) malaria parasites 08-02-2021 Vergunning verleend
IM-MV 20-020_000 Intervet International Ontwikkeling van een levend vaccin tegen Histophilus luchtweginfecties in kalveren Ontwerpbesluit genomen